Literature DB >> 17408373

Bacterial ghosts as adjuvant particles.

Eva M Riedmann1, Jennelle M Kyd, Allan W Cripps, Werner Lubitz.   

Abstract

The development of more advanced and effective vaccines is of great interest in modern medicine. These new-generation vaccines, based on recombinant proteins or DNA, are often less reactogenic and immunogenic than traditional vaccines. Thus, there is an urgent need for the development of new and improved adjuvants. Besides many other immunostimulatory components, the bacterial ghost (BG) system is currently under investigation as a potent vaccine delivery system with intrinsic adjuvant properties. BGs are nonliving cell envelope preparations from Gram-negative cells, devoid of cytoplasmic contents, while their cellular morphology and native surface antigenic structures remain preserved. Owing to the particulate nature of BGs and the fact that they contain many well known immune-stimulating compounds, BGs have the potential to enhance immune responses against ghost-delivered target antigens.

Mesh:

Substances:

Year:  2007        PMID: 17408373     DOI: 10.1586/14760584.6.2.241

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  21 in total

1.  Autotransporter-based antigen display in bacterial ghosts.

Authors:  Anna Hjelm; Bill Söderström; David Vikström; Wouter S P Jong; Joen Luirink; Jan-Willem de Gier
Journal:  Appl Environ Microbiol       Date:  2014-11-14       Impact factor: 4.792

Review 2.  The Bacterial Ghost platform system: production and applications.

Authors:  Timo Langemann; Verena Juliana Koller; Abbas Muhammad; Pavol Kudela; Ulrike Beate Mayr; Werner Lubitz
Journal:  Bioeng Bugs       Date:  2010 Sep-Oct

3.  Protection of piglets by a Haemophilus parasuis ghost vaccine against homologous challenge.

Authors:  Mingming Hu; Yanhe Zhang; Fang Xie; Gang Li; Jianjun Li; Wei Si; Siguo Liu; Shouping Hu; Zhuo Zhang; Nan Shen; Chunlai Wang
Journal:  Clin Vaccine Immunol       Date:  2013-03-27

4.  Generation of a Novel Staphylococcus aureus Ghost Vaccine and Examination of Its Immunogenicity against Virulent Challenge in Rats.

Authors:  Nagarajan Vinod; Sung Oh; Hyun Jung Park; Jung Mo Koo; Chang Won Choi; Sei Chang Kim
Journal:  Infect Immun       Date:  2015-05-11       Impact factor: 3.441

5.  A Vibrio cholerae ghost-based subunit vaccine induces cross-protective chlamydial immunity that is enhanced by CTA2B, the nontoxic derivative of cholera toxin.

Authors:  Eno E Ekong; Daniel N Okenu; Jayanti Mania-Pramanik; Qing He; Joseph U Igietseme; Godwin A Ananaba; Deborah Lyn; Carolyn Black; Francis O Eko
Journal:  FEMS Immunol Med Microbiol       Date:  2008-11-18

Review 6.  Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines?

Authors:  Sharan Bobbala; Sarah Hook
Journal:  Pharm Res       Date:  2016-07-05       Impact factor: 4.580

7.  Generation of biotechnology-derived Flavobacterium columnare ghosts by PhiX174 gene E-mediated inactivation and the potential as vaccine candidates against infection in grass carp.

Authors:  Wenxing Zhu; Guiwen Yang; Yuyu Zhang; Jinduo Yuan; Liguo An
Journal:  J Biomed Biotechnol       Date:  2012-06-10

8.  Novel fusion antigen displayed-bacterial ghosts vaccine candidate against infection of Escherichia coli O157:H7.

Authors:  Kun Cai; Wei Tu; Yuenan Liu; Tao Li; Hui Wang
Journal:  Sci Rep       Date:  2015-12-02       Impact factor: 4.379

Review 9.  Harnessing the potential of bacterial ghost for the effective delivery of drugs and biotherapeutics.

Authors:  Aditya Ganeshpurkar; Ankit Ganeshpurkar; Vikas Pandey; Abhishek Agnihotri; Divya Bansal; Nazneen Dubey
Journal:  Int J Pharm Investig       Date:  2014-01

10.  Rectal single dose immunization of mice with Escherichia coli O157:H7 bacterial ghosts induces efficient humoral and cellular immune responses and protects against the lethal heterologous challenge.

Authors:  Ulrike Beate Mayr; Pavol Kudela; Alena Atrasheuskaya; Eugenij Bukin; Georgy Ignatyev; Werner Lubitz
Journal:  Microb Biotechnol       Date:  2011-11-22       Impact factor: 5.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.